This week's BIO CEO conference is the largest conference of publicly traded biotech companies, and in this video, Motley Fool health care bureau chief Brenton Flynn highlights some takeaways from the conference. He discusses Celgene CEO Bob Hugin's fireside chat at the beginning of the conference, where he told investors about the company's FDA approval for its relapsed/refractory multiple myeloma drug Pomalyst. Hugin also discussed why he doesn't see Onyx's drug Krypolis to be a direct competitor, and how Celgene intends to maximize the opportunity it has with its top-selling drug, Revlimid.
Should you buy the Celgene hype?
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.
The article Celgene's CEO Talks New Approvals, Future Opportunities originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.